FDA drug review meetings missed, generic approvals slow, medical device development stalls (July 7, 2025 )
July 7, 2025 — A ProPublica investigation documented how the FDA's gutted capacity was cascading into concrete drug safety and development failures: the agency had already missed or postponed critical meetings with drug developers due to a shortage of reviewers, disrupting the Prescription Drug User Fee Act (PDUFA) process through which industry fees fund the agency's drug review work. Pre-application meetings — in which FDA reviewers advise companies on trial design and regulatory pathway — were being cancelled or significantly delayed, with the uncertainty making approval timelines unpredictable for the first time in a generation.
The Center for Devices and Radiological Health (CDRH) had curtailed its Q-Submission (Q-Sub) program, replacing real-time meetings between device developers and FDA staff with written-only feedback. For medical device companies — particularly startups developing novel diagnostics, surgical tools, and implantables — the change meant months-long delays at critical decision points, with some abandoning U.S. development pathways in favor of European regulatory approval first. The cuts to inspection support staff meant foreign drug factory audits were being deferred, with inspectors handling travel logistics independently and burning out on a pace the GAO had already identified as unsustainable.
The consequences for generic drug approvals — which account for about 90 percent of all prescriptions dispensed in the United States and are the primary mechanism for reducing drug costs — were particularly significant. With fewer reviewers and more uncertain timelines, companies filing Abbreviated New Drug Applications (ANDAs) for generic versions of brand drugs faced longer waits, effectively extending the period of brand-name market exclusivity and keeping costs higher for patients and insurers. The administration had simultaneously eliminated programs designed to support faster generic entry as part of its broader FDA staffing cuts.
| https://www.cancertherapyadvisor.com/features/fda-layoffs-could-compromise-safety-of-medications-made-at-foreign-factories-inspectors-say/ |